Journal of NeuroVirology

, Volume 21, Issue 6, pp 702–705 | Cite as

2nd International Conference on Progressive Multifocal Leukoencephalopathy (PML) 2015: JCV virology, progressive multifocal leukoencephalopathy pathogenesis, diagnosis and risk stratification, and new approaches to prevention and treatment

  • Andriani C. PateraEmail author
  • Scott L. Butler
  • Paola Cinque
  • David B. Clifford
  • Robert Elston
  • Robert L. Garcea
  • Eugene O. Major
  • Dejan Pavlovic
  • Ilse S. Peterson
  • Anne M. Ryan
  • Kenneth L. Tyler
  • Thomas Weber
  • on behalf of the PML Consortium
Meeting Report

Conference aims

Progressive multifocal leukoencephalopathy (PML) is a rare but serious demyelinating disease of the brain that can result in severe disability or death. PML is caused by infection of oligodendrocytes by the neuropathogenic form of JC polyomavirus (JCV). There is a high prevalence of chronic but asymptomatic JCV infection in the general population. However, the incidence of PML is relatively low due to the requirement for transformation of an otherwise non-pathogenic virus to a neuropathogenic form, which is a slowly evolving process typically occuring in individuals with compromised immune system.

Notable progress has been made in defining risk factors for PML, but advances in diagnosis, accurate susceptibility prediction, prevention, and treatment lag. The “2nd International Conference on Progressive Multifocal Leukoencephalopathy,” held in Mölndal, Sweden, on August 25–26, 2015, brought together scientists, clinicians, and regulatory experts from academia, industry,...


Progressive Multifocal Leukoencephalopathy Natalizumab Cidofovir Progressive Multifocal Leukoencephalopathy Maraviroc 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors would like to acknowledge the Progressive Multifocal Leukoencephalopathy Consortium’s Board of Directors for its support of the research conference; the conference speakers and attendees who contributed to the discussions presented herein; Drs. Len Calabrese and Marianne Gerber, who also contributed to organization of the conference; and the PML Consortium Secretariat and AstraZeneca for their organizational support.

Compliance with ethical standards

Conflict of interest

AstraZeneca/MedImmune, Pfizer, and Roche are PML Consortium member companies. D. Pavlovic and M. Gerber are members of the PMLC Clinical Working Group. A. Patera, S. Butler, and R. Elston are members of the PMLC Research Working Group. Dejan Pavlovic and Andriani Patera are employees of MedImmune, the global biologics research and development arm of AstraZeneca, and own stock in AstraZeneca. Robert Elston and Marianne Gerber are employees of and own stock in F. Hoffmann-La Roche AG. Scott Butler and Anne Ryan are employees of and own stock in Pfizer Inc.

David B. Clifford, Robert L. Garcea, Eugene O. Major, Kenneth L. Tyler, and Thomas Weber are members of the PML Consortium Scientific Advisory Board. Kenneth Tyler has served as a scientific consultant or scientific advisory board member for Hoffman La Roche, Biogen, Genentech, Johnson & Johnson, and Pfizer.

Paola Cinque is a PML Consortium grantee and has received funding from the Consortium to support her research.

Ilse Peterson is an employee of Drinker Biddle & Reath, LLP, which serves as the PML Consortium Secretariat, and has no conflicts of interest to report.

Related online content

Since work described herein is primarily unpublished, titles of presentations are referenced below to allow readers to view the recorded presentations posted on

  1. Atwood W. Human polyoma virus receptor distribution. Session 1Google Scholar
  2. Berger J. PML associated with neurologic therapies. Session 3Google Scholar
  3. Buck C. Developing vaccines against JC polyomavirus. Session 4Google Scholar
  4. Clifford D. PML treatment/IRIS. Session 4Google Scholar
  5. DiMaio D. Cellular factors required for infection by small DNA viruses. Session 1Google Scholar
  6. Enquist L. Axons, the front line sensors of alpha herpes virus PNS invasion. Session 1Google Scholar
  7. Hirsch H. Testing JC and BK PyV antibody responses: why and how. Session 2Google Scholar
  8. Imperiale M. Trafficking of BKPyV to the nucleus. Session 1Google Scholar
  9. Legatie O. Biomarkers for JCV infection. Session 3Google Scholar
  10. Lindberg R. Molecular markers for a PML risk in natalizumab treated MS patients. Session 3Google Scholar
  11. Martin R. T cell immunity in PML and MS. Session 3Google Scholar
  12. McGavern D. T cell surveillance of the acute and persistently infected brain. Session 2Google Scholar
  13. Molloy E. PML associated with autoimmune and autoinflammatory diseases. Session 3Google Scholar
  14. Nath A. Antisense to JCV. Session 4Google Scholar
  15. Neu U. Polyomavirus structure, receptor interactions. Session 1Google Scholar
  16. Olsson T. Host genetics in the control of JCV infection. Session 3Google Scholar
  17. Ransohoff R. Blood brain barrier, CNS immune surveillance. Session 2Google Scholar
  18. Schneider-Hohendorf T. Natalizumab treatment is associated with increased anti-JCV antibody seroconversion. Session 3Google Scholar
  19. Shishido-Hara Y. JC viral inclusions in PML: PML-NBs. Session 2Google Scholar
  20. Werner M. Host Abelson-kinase inhibitors. Session 4Google Scholar

Copyright information

© Journal of NeuroVirology, Inc. 2015

Authors and Affiliations

  • Andriani C. Patera
    • 7
    Email author
  • Scott L. Butler
    • 1
  • Paola Cinque
    • 2
  • David B. Clifford
    • 3
  • Robert Elston
    • 4
  • Robert L. Garcea
    • 5
  • Eugene O. Major
    • 6
  • Dejan Pavlovic
    • 8
  • Ilse S. Peterson
    • 9
  • Anne M. Ryan
    • 10
  • Kenneth L. Tyler
    • 11
  • Thomas Weber
    • 12
  • on behalf of the PML Consortium
  1. 1.Inflammation and ImmunologyWorldwide Research and Development, Pfizer IncCambridgeUSA
  2. 2.Department of Infectious DiseasesSan Raffaele Scientific InstituteMilanItaly
  3. 3.Washington University School of MedicineSt. LouisUSA
  4. 4.Roche Pharma Research & Early DevelopmentRoche Products LimitedWelwyn Garden CityUK
  5. 5.Department of Molecular, Cellular, and Developmental Biology and the BioFrontiers InstituteUniversity of Colorado BoulderBoulderUSA
  6. 6.NINDSNIHDarnestownUSA
  7. 7.Infectious Disease and VaccinesMedImmune LLCGaithersburgUSA
  8. 8.Global Regulatory Affairs, Patient Safety and Quality AssuranceAstraZenecaGaithersburgUSA
  9. 9.PML Consortium SecretariatDrinker Biddle & Reath LLPWashingtonUSA
  10. 10.Drug Safety R&D, Worldwide Research and DevelopmentPfizer IncGrotonUSA
  11. 11.Department of NeurologyUniversity of Colorado School of MedicineAuroraUSA
  12. 12.Department of NeurologyMarienkrankenhausHamburgGermany

Personalised recommendations